Glycaemic control with liraglutide: The phase 3 trial programme

Philip Raskin, P. F. Mora

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Aims: To review the efficacy and safety of liraglutide from the phase 3 trials, focusing primarily on glycaemic control. Key findings: Liraglutide was shown to reduce glycated haemoglobin (HbA1c) levels by up to 1.5% from baseline, significantly more than the comparators sitagliptin (-0.9%), glimepiride (-0.5%), rosiglitazone (-0.4%), insulin glargine (-1.1%) and exenatide (-0.8%). Both fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) levels were shown to be significantly reduced from baseline [up to -2.4 mmoll (-43.2 mgdl) and -2.7 mmoll (-48.6 mgdl) for FPG and PPG in the liraglutide 1.8 mg group, respectively]. Changes in HbA1c, FPG and PPG levels were sustained for the duration of the studies (up to 52 weeks). The glycaemic control offered by liraglutide was not associated with an increased rate of minor hypoglycaemic events compared with comparator treatments, with rates significantly lower than those of glimepiride and exenatide. Major hypoglycaemic events were rare and only occurred in combination with a sulfonylurea. Nausea was the most frequent adverse event, but subsided within the first few weeks. Conclusions: Liraglutide has been shown to offer effective glycaemic control for patients with type 2 diabetes and is appropriate for use across the conventional continuum of care. Despite the sustained reductions in HbA1c, FPG and PPG levels achieved with liraglutide, rates of minor hypoglycaemia were generally low, although the risk increased when combined with a sulfonylurea. Liraglutide is therefore a promising new option for the treatment of type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)21-27
Number of pages7
JournalInternational Journal of Clinical Practice
Issue numberSUPPL. 167
StatePublished - Oct 2010

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Glycaemic control with liraglutide: The phase 3 trial programme'. Together they form a unique fingerprint.

Cite this